Vaccine value profile for Group B streptococcus
Caroline Trotter(University of Bristol), Philipp Lambach(World Health Organization), Simon R. Procter, Eve Nakabembe(Washington University in St. Louis), Kirsty Le Doaré(St George's, University of London), Mark R. Alderson(Program for Appropriate Technology in Health), Musa Sekikubo(Makerere University), Ziyaad Dangor(South African Medical Research Council), Margaret Ip(Chinese University of Hong Kong)
Cited by 37
Related Papers
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study
|The Lancet Global Health|2020|1.2k
Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
|Nature|1994|600
Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data
|The Lancet Digital Health|2021|536
Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses
|Clinical Infectious Diseases|2017|453
Understanding the gut microbiota and sarcopenia: a systematic review
|Journal of Cachexia Sarcopenia and Muscle|2021|340